Literature DB >> 28506515

Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate.

Ashaben Patel1, Steven M Erb2, Linda Strange2, Ravi S Shukla1, Ozan S Kumru1, Lee Smith3, Paul Nelson4, Sangeeta B Joshi1, Jill A Livengood5, David B Volkin6.   

Abstract

A combination experimental approach, utilizing semi-empirical excipient screening followed by statistical modeling using design of experiments (DOE), was undertaken to identify stabilizing candidate formulations for a lyophilized live attenuated Flavivirus vaccine candidate. Various potential pharmaceutical compounds used in either marketed or investigative live attenuated viral vaccine formulations were first identified. The ability of additives from different categories of excipients, either alone or in combination, were then evaluated for their ability to stabilize virus against freeze-thaw, freeze-drying, and accelerated storage (25°C) stresses by measuring infectious virus titer. An exploratory data analysis and predictive DOE modeling approach was subsequently undertaken to gain a better understanding of the interplay between the key excipients and stability of virus as well as to determine which combinations were interacting to improve virus stability. The lead excipient combinations were identified and tested for stabilizing effects using a tetravalent mixture of viruses in accelerated and real time (2-8°C) stability studies. This work demonstrates the utility of combining semi-empirical excipient screening and DOE experimental design strategies in the formulation development of lyophilized live attenuated viral vaccine candidates.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Keywords:  Dengue; Design of experiments; Excipients; Flavivirus; Formulation; Live attenuated vaccine; Lyophilization; Stability; Vaccine; Virus

Mesh:

Substances:

Year:  2017        PMID: 28506515     DOI: 10.1016/j.vaccine.2017.04.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production.

Authors:  Yang Sun; Lingling Huang; Jianqi Nie; Kai Feng; Yupeng Liu; Zhonghu Bai
Journal:  AMB Express       Date:  2022-05-14       Impact factor: 4.126

2.  Effect of Formulation Variables on the Stability of a Live, Rotavirus (RV3-BB) Vaccine Candidate using in vitro Gastric Digestion Models to Mimic Oral Delivery.

Authors:  Prashant Kumar; Swathi R Pullagurla; Ashaben Patel; Ravi S Shukla; Christopher Bird; Ozan S Kumru; Ahd Hamidi; Femke Hoeksema; Christopher Yallop; Julie E Bines; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2020-10-07       Impact factor: 3.534

3.  Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.

Authors:  Ozan S Kumru; Soraia Saleh-Birdjandi; Lorena R Antunez; Eddy Sayeed; David Robinson; Sjoerd van den Worm; Geoffrey S Diemer; Wilma Perez; Patrizia Caposio; Klaus Früh; Sangeeta B Joshi; David B Volkin
Journal:  Vaccine       Date:  2019-09-20       Impact factor: 3.641

4.  Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus.

Authors:  Roberta Di Benedetto; Francesca Mancini; Martina Carducci; Gianmarco Gasperini; Danilo Gomes Moriel; Allan Saul; Francesca Necchi; Rino Rappuoli; Francesca Micoli
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

5.  Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis.

Authors:  Lucas S Shores; Sean H Kelly; Kelly M Hainline; Jutamas Suwanpradid; Amanda S MacLeod; Joel H Collier
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.